Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01674582|
Recruitment Status : Recruiting
First Posted : August 29, 2012
Last Update Posted : March 12, 2018
|Condition or disease||Intervention/treatment||Phase|
|Intracranial Tumor||Other: MRI, neuropsychological evaluation, blood sampling||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters.|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||February 2019|
|Estimated Study Completion Date :||February 2019|
|MRI, Neuropsychological testing||
Other: MRI, neuropsychological evaluation, blood sampling
MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.
Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years.
- Early prediction of treatment response based on MRI parameters. [ Time Frame: Three weeks compared to baseline. ]
- Neuropsychological function. [ Time Frame: Month 3, 12, and 18 compared to baseline ]Neuropsychological testing to evaluate the correlation between MRI results and neuropsychological status in participating patients. This applies for 80 patients of 150 of the patient population.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01674582
|Contact: Pia Maly Sundgren, MD, PhD||+46 46 17 10 firstname.lastname@example.org|
|Contact: Sara Kinhult, MD, PhD||+46 46 17 75 email@example.com|
|Lund University Hospital||Recruiting|
|Lund, Sweden, 221 85|
|Contact: Danielle van Westen, MD, PhD +46 46 firstname.lastname@example.org|
|Contact: Sara Kinhult, MD, PhD +46 46 17 75 20 email@example.com|
|Principal Investigator: Danielle van Westen, MD, PhD|
|Principal Investigator:||Pia Maly Sundgren, MD. PhD||Skåne University Hospital-Lund|